Table 6.

Overview of successful therapy strategies for prevention or elimination of ADAs in patients with LSDs

Disease	Target	Drug Components	Reference
Immune tolerance induction in ERT-naïve patients
FD	Immunosuppression due to transplantations	Methylprednisolone with azathioprine, calcineurin inhibitors, mycophenolate-mofetil/mycophenolate acid	115
PD	B cell depletion	Rituximab, MTX, IVIG	118
PD	Immunosuppression, B cell depletion, mTOR inhibition	Methylprednisolone, rituximab, rapamycin, IVIG	112
PD	B cell depletion, immunomodulation	Rituximab, MTX, IVIG	117
PD	B cell depletion, immunomodulation	Rituximab, MTX, IVIG	114
Acute reduction of neutralizing ADAs
FD	Short-term ADA reduction by immunosuppression due to transplantations	Prednisolone, tacrolimus, mycophenolate-mofetil/mycophenolate acid	115
GD	Acute ADA reduction, immunosuppression	Plasma exchange (one plasma volume), cyclophosphamide, IVIG	116
PD	B cell depletion	Rituximab, MTX, IVIG	111
PD	Immunosuppression proteasome inhibition, B cell/plasma cell depletion	Cyclophosphamide, rituximab, bortezomib, MTX, IVIG	113
PD	Acute ADA reduction, immunosuppression	Cyclophosphamide, IVIG, plasma exchange	120
PD	B cell depletion	Rituximab, MTX, IVIG	119

PD, Pompe disease; IVIG, intravenous immunoglobulin; mTOR, mechanistic target of rapamycin; GD, Gaucher disease.